Cover Image
市場調查報告書

急性冠狀動脈症候群 (ACS) 治療藥的全球市場的競爭分析

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

出版商 Frost & Sullivan 商品編碼 330922
出版日期 內容資訊 英文 69 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性冠狀動脈症候群 (ACS) 治療藥的全球市場的競爭分析 A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
出版日期: 2015年05月20日 內容資訊: 英文 69 Pages
簡介

臨床實驗的最後階段有潛力的開發中產品的上市,成為急性冠狀動脈症候群 (ACS) 治療藥市場推動因素。

本報告提供全球各國的急性冠狀動脈症候群 (ACS) 治療藥主要的已上市/開發中產品的相關調查、各產品的到目前為止的開發、上市情形,及臨床實驗開發平台現況、過去、未來的產品上市時間軸、疾病的流行病學的資訊等彙整、 主要產品的特徵和銷售額預測 (今後11年份)之分析、推算。

第1章 摘要整理

第2章 調查手法及調查範圍

第3章 市場概要

  • 簡介
  • 流行病學

第4章 醫生治療指南

  • 醫生治療指南
  • 市場規模
  • 市場預測
  • 市場區隔

第5章 競爭情形:ACS治療藥 (已上市及開發中產品)

  • 概要
  • 已上市/開發中產品
  • 已上市產品:抗血小板療法
  • 開發中產品:抗血小板療法
  • 已上市產品:抗凝血酵素療法
  • 開發中產品:抗凝血酵素療法
  • 已上市產品:高血壓治療藥、降膽固醇藥
  • 開發中產品:高血壓治療藥、降膽固醇藥
  • 開發中產品:其他
  • 產品上市的時間軸
  • 專利到期

第6章 重要的第三階段臨床實驗

  • ACS治療藥:主要的進行中的臨床實驗/近來完成的臨床實驗
  • 值得關注的主要產品:摘要

第7章 產品開發動態即時看板系統 (主要已上市/第三階段產品)

  • Plavix (kuropudogureru):Bristol-Myers Squibb
  • Brilinta (chikagureroru):The Medicines Company
  • Angiomaxto:The Medicines Company
  • Zocor (辛伐他汀(simvastatin)):Merck
  • Xarelto (Rivaroxaban):Bayer
  • arirokumabu (RGN727):Sanofi & Regeneron
  • eborokumabu (Repatha):Amgen
  • evasetorapibu:Eli Lilly & Company
  • rosumapimodo:GSK

第8章 結論

第9章 附錄

第10章 關於FROST & SULLIVAN

目錄
Product Code: MB06-01-00-00-00

Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics

This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015-2025.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary-Key Findings
  • 2. Executive Summary-Key Findings (continued)
  • 3. Key Trends
  • 4. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. MARKET OVERVIEW

Market Overview

  • 1. Market Overview-Introduction
  • 2. Market Overview-Epidemiology
  • 3. Market Overview-Epidemiology (continued)
  • 4. Market Overview-Epidemiology (continued)

4. PHYSICIANS TREATMENT GUIDELINES

Physicians Treatment Guidelines

  • 1. Physicians Treatment Guidelines
  • 2. Physicians Treatment Guidelines (continued)
  • 3. Physicians Treatment Guidelines (continued)
  • 4. Physicians Treatment Guidelines (continued)
  • 5. Market Size
  • 6. Market Size-Segmentation
  • 7. Market Forecast
  • 8. Market Segmentation

5. COMPETITIVE LANDSCAPE-ACS THERAPEUTICS (MARKETED AND PIPELINE PRODUCTS)

Competitive Landscape-ACS Therapeutics (Marketed and Pipeline Products)

  • 1. Competitive Landscape Overview
  • 2. Competitive Landscape-Marketed and Pipeline Products
  • 3. Marketed Products-Anti-platelet Therapy
  • 4. Pipeline Products-Anti-platelet Therapy
  • 5. Marketed Products-Anti-thrombin Therapy
  • 6. Marketed Products-Anti-thrombin Therapy (continued)
  • 7. Pipeline Products-Anti-thrombin Therapy
  • 8. Marketed Products-Anti-hypertensives & Cholesterol Lowering Drugs
  • 9. Marketed Products-Anti-hypertensives & Cholesterol Lowering Drugs (continued)
  • 10. Pipeline Products-Anti-hypertensives & Cholesterol Lowering Drugs
  • 11. Pipeline Products-Others
  • 12. Product Launch Timeline
  • 13. Patent Expirations

6. PIVOTAL PHASE 3 TRIALS

Pivotal Phase 3 Trials

  • 1. ACS Therapeutics-Major Ongoing/Recently Completed Clinical Trials
  • 2. ACS Therapeutics-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 3. Summary of Key Products to Watch

7. PRODUCT DASHBOARD (KEY MARKETED AND PHASE 3 PRODUCTS)

Product Dashboard (Key Marketed and Phase 3 Products)

  • 1. Product Dashboard: Plavix (clopidogrel)-Bristol-Myers Squibb
  • 2. Product Dashboard: Brilinta (ticagrelor)-The Medicines Company
  • 3. Product Dashboard: Angiomax-The Medicines Company
  • 4. Product Dashboard: Zocor (simvastatin)-Merck
  • 5. Product Dashboard: Xarelto (rivaroxaban)-Bayer
  • 6. Product Dashboard: Alirocumab (RGN727)-Sanofi & Regeneron
  • 7. Product Dashboard: Evolocumab (Repatha)-Amgen
  • 8. Product Dashboard: Evacetrapib-Eli Lilly & Company
  • 9. Product Dashboard: Losmapimod-GSK

8. CONCLUSION

Conclusion

  • 1. Conclusions
  • 2. Legal Disclaimer

9. APPENDIX

Appendix

  • 1. Decision Support Database
  • 2. Decision Support Database (continued)
  • 3. Decision Support Database (continued)
  • 4. Decision Support Database (continued)

10. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top